Kang Yin, a reporter from the Securities Times.
On July 28th, Changchun Hi-Tech (000661), which is known as "herb grass", made the latest statement on whether the leading product growth hormone should be included in the collection.
Changchun Hi-Tech said that in view of the current situation, the company does not expect growth hormone products to be collected by the state in the short term, and only individual provinces plan to collect them, which has relatively little impact. Assuming that the collection policy is on the ground and the product price is falling, the company will strive to ensure the company's performance by improving the number of users. In addition, at present, there are only three manufacturers of growth hormone water needle products, and no other manufacturers have been found to declare related products. The company expects that the market competition pattern will not change greatly in the short term.
It will not be included in the collection for the time being.
Changchun Hi-tech was surveyed by 144 institutions on July 28. There are 72 fund management companies, 25 asset management companies, 19 investment companies and 12 securities companies. Changchun Hi-Tech is mainly engaged in the production and sales of biopharmaceutical and proprietary Chinese medicine. Jinsai Pharmaceutical, a subsidiary of Changchun Hi-Tech, is mainly engaged in the research, development, production and marketing of genetically engineered biological drugs, and its main products are recombinant human growth hormone for injection.
In the latest institutional research, Changchun Hi-Tech said that at present, the overall operation of the company is good, but it does not meet the criteria stipulated by the exchange that profits should be announced in a timely manner when the existence is profitable and the net profit is up or down by more than 50% compared with the same period last year, so the company did not disclose the relevant performance notice. Jinsai Pharmaceutical growth hormone products perform well in the aspects of new patients and existing patient maintenance, and the promotion and sales work related to adult indications of growth hormone is making steady progress.
Jinsai Pharmaceutical, a subsidiary of Changchun High-tech, whose main business is growth hormone, achieved 5.803 billion yuan in revenue and 2.76 billion yuan in net profit in 2020, accounting for 68% of Changchun's total revenue and 91% of net profit.
In addition, Changchun high-tech Baig biological varicella vaccine products in the second quarter were affected by factors such as the gradual implementation of large-scale centralized vaccination of COVID-19 vaccine across the country, and the shortage of warehouses and vaccination personnel in various centers for disease control and prevention. Performance has declined to a certain extent. At present, the company is actively promoting the sales of related products, and at the same time actively promoting the batch issuance and sales of nasal spray influenza vaccine products in the second half of the year. Huakang Pharmaceutical Co., Ltd. is in good condition, and there are fewer settlement projects in the first half of high-tech real estate.
Strive to expand all lines and new products
With regard to the current product planning of Jinsai Pharmaceutical Co., Ltd., Changchun Hi-Tech said that at present, Jinsai Pharmaceutical products mainly include growth hormone, recombinant human follicle stimulating hormone for injection, recombinant human granulocyte macrophage stimulating factor gel for external use (Jinfuning), and so on.
In terms of adult indications for growth hormone, Changchun Hi-Tech believes that the product has great market potential in the future, and the company actively expands the coverage of medical institutions and experts to enhance the awareness of experts and patients. strengthen the coverage in the departments of endocrinology, brain surgery and neurology, rehabilitation, andrology, gynecology and other departments of medical institutions, so as to enhance the application of products in mental health, improve metabolism, enhance sexual function and so on.
In terms of assisted reproduction, the company continues to improve the coverage of follicle-stimulating hormone products, while actively promoting the progress of long-acting follicle-stimulating hormone and other related products. In terms of wound healing, Jinfuning mainly promoted the field of burns in the previous year, and after full market research, the company believes that it has great potential in wound healing and other fields. the company will make use of the existing pediatric channels to strengthen the promotion of this product in related fields, and at the same time actively promote coverage in other fields such as medicine and beauty in the future.
For follow-up products, in the field of children's health, Jinsai Pharmaceutical will actively expand children's nutrition, metabolism, mental health and other products, and will cover children's health products, special medical foods, medical devices and so on in the future. In the field of Alzheimer's disease, we will actively promote the progress of Xinyuan evergreen Alzheimer's disease diagnosis kit, and will further expand the layout of related products in this field in the future. In the field of tumor treatment, the company will actively promote coverage in prostate cancer, breast cancer and other fields through products such as leuprolium methanesulfonate.
Changchun Hi-Tech said that Jinsai Pharmaceutical will strive to expand the R & D, production and sales of new products in all lines, and strive to launch 8-10 new products with an income of more than 100 million yuan in the past two years, so as to reduce the risk of relying on a single product. The continuous improvement of the business volume of existing products and new products will provide favorable support for the continuous growth of the company's performance in the future.